Supernus製藥 SUPN 深 滬
等待開盤 08-19 09:30:00 美东时间
42.975
+0.285
+0.67%
華盛通- 最 高43.695
- 今 開42.76
- 成交量 35.51万股
- 最 低 42.50
- 昨 收 42.69
- 總市值 24.06亿
- 52周最高 43.695
- 市盈率 靜 32.56
- 換手率 0.63%
- 52周最低 29.16
- 委 比 65.94%
- 總股本 5598.96万
- 歷史最高 61.25
- 量 比 0.53
- 振 幅 2.80%
- 歷史最低 4.30
- 每 手 1
- 風險率 2.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $46
Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $42 to $46.
08-06 22:14
Supernus Pharmaceuticals Raises FY2025 Sales Guidance from $600.000M-$630.000M to $670.000M-$700.000M vs $632.103M Est
Supernus Pharmaceuticals (NASDAQ:SUPN) raises FY2025 sales outlook from $600.000 million-$630.000 million to $670.000 million-$700.000 million vs $632.103 million estimate.
08-06 04:27
Supernus Pharmaceuticals Q2 EPS $0.40 Beats $0.11 Estimate, Sales $180.916M Beat $154.061M Estimate
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $0.11 by 273.83 percent. This is a 11.11 percent increase over earnings of $0.36 per
08-06 04:09
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Supernus Pharmaceuticals completed its acquisition of Sage Therapeutics, enhancing its neuropsychiatric portfolio with ZURZUVAE® (zuranolone), the first FDA-approved oral treatment for postpartum depression. The deal diversifies Supernus' revenue base, adds a CNS discovery platform, and is projected to generate up to $200 million in annual cost synergies, becoming accretive in 2026. The acquisition also includes contingent value rights for Sage s...
07-31 12:44
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
Supernus Pharmaceuticals announced the expiration of the Hart-Scott-Rodino Act waiting period for its proposed acquisition of Sage Therapeutics. The $8.50 cash offer plus a contingent value right (CVR) for Sage's shares remains subject to certain conditions. The CVR includes potential payments tied to regulatory milestones and U.S. sales targets for ZURZUVAE, with total potential value up to $3.50 per share. The tender offer expires July 30, 2025...
07-28 12:25
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
Supernus Pharmaceuticals, Inc. announced it will report second-quarter 2025 financial and business results after market close on August 5, 2025. A conference call with CEO Jack Khattar and CFO Tim Dec will follow at 4:30 p.m. ET, with a live webcast available on the company’s Investor Relations website. A replay will be accessible for 60 days.
07-22 20:30
Supernus to acquire depression drugmaker Sage
Supernus Pharmaceuticals (NASDAQ:SUPN) has agreed to acquire depression drugmaker Sage Therapeutics (NASDAQ:SAGE) for a total consideration of up to $795M, or $12 per share, in an all-cash deal, the c...
06-16 19:27
Supernus Pharmaceuticals Agrees To Buy Sage Therapeutics For $8.50/Share Plus One Contingent Value Right Worth Up To $3.50 Per Share In Cash, For Total Consideration Of $12/Share
Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative
06-16 19:02
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
Supernus Pharmaceuticals has agreed to acquire Sage Therapeutics for up to $12.00 per share, valuing the deal at approximately $795 million. The transaction includes an upfront cash payment of $8.50 per share and contingent value rights worth up to $3.50 per share. Supernus expects the acquisition to strengthen its psychiatry portfolio with Sage’s ZURZUVAE, a treatment for postpartum depression, and bring significant revenue growth and cost syner...
06-16 11:00
